I am upgrading STERIS to a 'Buy' with a fair value of $240 per share due to the recent stock price pullback and solid growth prospects. STERIS reported 7.2% organic revenue growth and 5.4% adjusted ...

STERIS’ Healthcare segment is gaining from the successful market adoption of its comprehensive offerings, including infection prevention consumables and capital equipment. Further, its services to ...

Daniel Carestio, President and CEO, highlighted an increased outlook for fiscal 2026 due to strong first-half performance, noting, "We now anticipate approximately 8% to 9% as reported revenue growth, ...

It has been about a month since the last earnings report for Steris (STE). Shares have lost about 2.2% in that time frame, underperforming the S&P 500. Will the recent negative trend continue leading ...

Operator: Good day, everybody, and welcome to the STERIS plc Second Quarter 2025 Earnings Call. [Operator Instructions] Please note, today’s event is being recorded. I would now like to turn the call ...

Piper Sandler raised the firm’s price target on Steris (STE) to $265 from $260 and keeps an Overweight rating on the shares. The firm sees the quarter as solid for Steris’ HC franchise, and believes ...

Narrow-moat Steris had a good fiscal third quarter, moderately exceeding both our expectations and consensus aggregated by FactSet. While operating costs were a bit higher than anticipated--due to ...

STERIS plc isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here). Operator: Good morning everyone and welcome to the STERIS plc Third Quarter ...

STERIS’s fourth quarter results received a negative reaction from the market despite surpassing Wall Street’s revenue expectations and reporting adjusted earnings per share in line with consensus.